Onconetix Inc
Biotechnology
Onconetix Inc (ONCO) Stock News
The latest ONCO headlines and market coverage — 3 recent stories, updated throughout the day.
- Benzinga·Neutral
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?
Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. However, the stock has dropped 99.11% over the past 12 months and currently trades at its annual low.
- Benzinga·
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?
Onconetix Inc. (NASDAQ: ONCO ) shares soared 23.65% to $0.38 in after-hours trading on Monday. The Ohio-based biotechnology company reversed a steep 18.26% regular session decline, closing the stock at $0.31, according to Benzinga Pro data. Clinical Validation On May 13, Onconetix reported first-quarter 2026 operational progress from its fully-owned Swiss subsidiary, Proteomedix AG , developer of Proclarix, a CE-IVD certified blood test designed to identify clinically significant prostate cancer in combination with prostate-specific antigen (PSA) testing. Prostate cancer is the most commonly diagnosed cancer in men in most countries around the world and places a significant burden on patients and healthcare systems. A National Institutes of Health 2019 report found that in 2018, over 1 million new cases of prostate cancer were reported globally, accounting for 7.1% of all cancers diagnosed in men. According to the ... Full story available on Benzinga.com
- GlobeNewswire Inc.·
CONCORDE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – CIGL, YOOV
Rosen Law Firm reminds investors of Concorde International Group Ltd. (NASDAQ: CIGL, YOOV) who purchased securities between April 21, 2025 and July 14, 2025 of the May 20, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company was subject to a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and materially misleading statements about business operations.